share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Secora Michael

SEC announcement ·  Apr 18 17:17
Summary by Moomoo AI
Michael Secora, the Chief Financial Officer of Recursion Pharmaceuticals, Inc. (RXRX), completed a series of transactions involving the company's Class A Common Stock on April 16 and 17, 2024. Secora acquired a total of 75,000 shares through the exercise of derivative securities at a price of $2.22 per share. Concurrently, he sold 25,000 shares on April 16 at a price of $7.6663 per share and an additional 23,124 shares on April 17 at $7.583 per share. Following these transactions, Secora's direct holdings in Recursion Pharmaceuticals amounted to 1,231,055 shares. The total market value of the disposed shares was calculated to be approximately $367,006.79.
Michael Secora, the Chief Financial Officer of Recursion Pharmaceuticals, Inc. (RXRX), completed a series of transactions involving the company's Class A Common Stock on April 16 and 17, 2024. Secora acquired a total of 75,000 shares through the exercise of derivative securities at a price of $2.22 per share. Concurrently, he sold 25,000 shares on April 16 at a price of $7.6663 per share and an additional 23,124 shares on April 17 at $7.583 per share. Following these transactions, Secora's direct holdings in Recursion Pharmaceuticals amounted to 1,231,055 shares. The total market value of the disposed shares was calculated to be approximately $367,006.79.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more